Ambulatory Blood Pressure Monitoring

William White

Role of PCSK9 Inhibitors in Diabetes

Stephen Kopecky

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

Lp(a): When to Measure it and What to Do About it

Canadian Collaborative Research Network

M. O'Donoghue

CT Coronary Calcium Scoring, Hard Plaque and Soft Plaque Visualizati…

Scripps Health

M. Budoff

Advancing Type 2 Diabetes Care with Omnipod® 5

Omnipod®

V. Shah, D. Kruger, T. Ly

Should Colchicine Become Standard Therapy for CAD?

Canadian Collaborative Research Network

P. Ridker

Role of Coronary Calcification and Risk Stratification

The Texas Heart Institute

E. Hernandez

Recent Cholesterol Guidelines and Integration into Clinical Practice

The North American Thrombosis Forum (NATF)

J. Plutzky, L. Braun, J. Ross

Updated Lipid Guidelines and Therapy

Complex Coronary Cases

I. Fergus

Optimizing Omnipod® 5 for Better Patient Outcomes (featuring Jennife…

Omnipod®

J. Okemah

ACC 2022: Triple Therapy - When to Use and How Long

ACC 2022 Conference Coverage

D. Kumbhani

Do Triglycerides Cause Heart Disease?

National Lipid Association

I. Goldberg

AHA 2022: Cardiovascular Benefit of Lowering LDL Cholesterol Below 4…

AHA 2022 Conference Coverage

N. Marston

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients Wi…

AHA 2022 Conference Coverage

K. Ray

Cardiology’s Biggest Controversy: The Lumen or the Wall - the Curiou…

Cedars Sinai

J. Forrester

Mind over diabetes: a psychologist’s take on the freedom of Omnipod®…

Omnipod®

M. Heyman

Directions of Cardiology in the Next Decade: 2022-2032

Houston Methodist DeBakey Heart and Vascular Center

E. Braunwald

Type 2 Diabetes and Omnipod® 5--Unveiling SECURE T2D

Omnipod®

F. Pasquel

The Deadly Paradox: Current Practice, Driven by Guidelines, Is Not A…

Michael Makover